Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount
You may also be interested in...
Sun Pharma To Foray Into Large European Markets To Sell Hospital Products
MUMBAI - Sun Pharmaceutical - the most highly valued Indian drug company - is soon establishing its direct presence in Europe. The move comes years after Sun Pharma's top Indian rivals Ranbaxy, Dr. Reddy's and Wockhardt set up their operations in Europe through organic route or by acquiring established generic drug businesses
Sun Pharma To Foray Into Large European Markets To Sell Hospital Products
MUMBAI - Sun Pharmaceutical - the most highly valued Indian drug company - is soon establishing its direct presence in Europe. The move comes years after Sun Pharma's top Indian rivals Ranbaxy, Dr. Reddy's and Wockhardt set up their operations in Europe through organic route or by acquiring established generic drug businesses
Taro Rejects Sun Pharma’s Settlement Offer; Suggests Shareholder Referendum
MUMBAI - Israeli generic drug maker Taro has rejected Sun Pharma's proposal for a merger at a value of $9.50 per share or increase the offer price for non-promoter shares to $9 for every ordinary share. In a letter written to Sun Pharma's Chairman and Managing Director Dilip Shanghvi, Taro Chairman Barrie Levitt said the Taro board of directors "did not view the two options" set forth in the proposal as constructive or even "in the ballpark